Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Systemic Bi-Specific NanoAb
- Development stage
- Preclinical
- Lead developer
- Scinai Immunotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Systemic Bi-Specific NanoAb is a preclinical-stage VHH-based bispecific antibody (nanobody) being developed by Scinai Bioservices, a division of Scinai Immunotherapeutics. The molecule is engineered in a VHH-Fc format to simultaneously neutralize the pro-inflammatory cytokines IL-17A and IL-17F, along with a third undisclosed target, to provide enhanced anti-inflammatory activity. It is intended for systemic administration as a long-acting biologic for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and hidradenitis suppurativa. The dual-target architecture is designed to offer a differentiated mechanism and dosing profile compared to existing single-target IL-17 therapies. As of late 2025, the program has applied for a €15 million grant under the EU STEP program to support its development.
- Other names
- IL-17A/F x undisclosed target bispecific nanobody
02
Targets
IL17F (Interleukin 17F)IL-17A (Interleukin-17A)
Beyond the preview
Go deeper on Systemic Bi-Specific NanoAb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Systemic Bi-Specific NanoAb.